India Gears Up To Monitor Safety Of New Drugs; Launches Nationwide Pharmacovigilance Program
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - At a time when GlaxoSmithKline's anti-diabetes drug Avandia has come under serious fire over its long-term cardiovascular safety profile, India's Central Drugs Standard Control Organization has launched an ambitious pharmacovigilance program for monitoring safety of newly introduced medicines
You may also be interested in...
India's DCGI Halts Avandia's TIDE Trial Aimed At Proving CV Safety; Steps Up Review of "Controversial Drugs" Sold In India
MUMBAI - GlaxoSmithKline may be temporarily relieved after U.S. FDA's joint advisory committee recommended that GSK's controversial anti-diabetes drug Avandia (rosiglitazone) remain on the market; but dealing with the product seems to be getting tougher for the company in countries like India
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).